Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.

Saab, Sammy

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. [electronic resource] - Journal of medical economics Aug 2016 - 795-805 p. digital

Publication Type: Journal Article

1941-837X

10.1080/13696998.2016.1176030 doi


2-Naphthylamine
Adult
Aged
Aged, 80 and over
Anilides--economics
Antiviral Agents--administration & dosage
Benzimidazoles--economics
Carbamates--economics
Carcinoma, Hepatocellular--economics
Cost-Benefit Analysis
Cyclopropanes
Drug Therapy, Combination
Female
Fibrosis--economics
Fluorenes--economics
Genotype
Hepacivirus--genetics
Hepatitis C, Chronic--drug therapy
Humans
Lactams, Macrocyclic
Liver Neoplasms--economics
Macrocyclic Compounds--economics
Male
Markov Chains
Middle Aged
Models, Econometric
Proline--analogs & derivatives
Quality-Adjusted Life Years
Ribavirin--economics
Simeprevir
Sofosbuvir--economics
Sulfonamides--economics
Uracil--analogs & derivatives
Valine